
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio is anticipated to have a positive outlook, backed by its promising product pipeline of allogeneic gamma delta T cell therapies, including prulacabtagene leucel for autoimmune diseases and ADI-212 for prostate-specific membrane antigen. Additionally, its preliminary Phase 1 data for prula-cel has shown significant efficacy and a benign safety profile in treating lupus nephritis and systemic lupus erythematosus, with potential for future upside in other autoimmune indications. Multiple key data updates are expected in 2026, including the initiation of a Phase 1 study for ADI-212 in metastatic castration-resistant prostate cancer.
Bears say
Adicet Bio is facing a number of fundamental risks that may hinder the potential success of its main product candidate, prulacabtagene leucel (prula-cel), in treating autoimmune diseases. These include potential shortcomings in both efficacy and safety, as well as competition from other companies developing similar CD19-targeted CAR-T agents. Additionally, regulatory and manufacturing risks could lead to delays or roadblocks in the development and commercialization of Adicet's pipeline. All of these factors contribute to the overall negative outlook for Adicet Bio's stock.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares